Bavarian Nordic A/S (BVNRY) Analysts See $-0.18 EPS

March 20, 2018 - By Nellie Frank

 Bavarian Nordic A/S (BVNRY) Analysts See $ 0.18 EPS

Analysts expect Bavarian Nordic A/S (OTCMKTS:BVNRY) to report $-0.18 EPS on March, 21.They anticipate $0.32 EPS change or 228.57 % from last quarter’s $0.14 EPS. The stock decreased 3.24% or $0.37 during the last trading session, reaching $11.06. About shares traded. Bavarian Nordic A/S (OTCMKTS:BVNRY) has 0.00% since March 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Bavarian Nordic A/S, a biotechnology company, develops, makes, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company has market cap of $1.09 billion. The firm markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It has a 35.26 P/E ratio. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.